Biogen Pharmachem Industries (531752) Q3 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 25/26 earnings summary
11 Feb, 2026Executive summary
Board approved unaudited financial results for the quarter and nine months ended December 31, 2025.
Significant events and developments
Board meeting held on February 11, 2026, to consider and approve financial results.
Risk factors and uncertainties
Independent auditor's review found no material misstatements or non-compliance in the financial statements.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Biogen Pharmachem Industries
- Quarterly unaudited results approved with no material misstatements found by auditors.531752
Q1 26/27 - Revenue and net profit surged year-over-year, with a strong audit opinion and asset growth.531752Q4 25/26
- Q2 FY26 saw a sharp revenue drop, net loss, and higher equity, with strong cash flows.531752Q2 25/26
- Revenue and net profit rebounded sharply year-over-year, with EPS turning positive.531752Q1 25/26
- Q2 FY25 saw Biogen Pharmachem swing to a net loss with declining income and equity.531752Q2 24/25
- Q1 FY25 revenue turned negative and net loss reached ₹15.83 lakhs, reversing prior gains.531752Q1 24/25
- Q3 FY25 saw a net loss and major board changes at Biogen Pharmachem Industries.531752Q3 24/25
- FY25 saw Biogen Pharmachem return to profit with robust revenue growth and capital inflow.531752Q4 24/25